I have been writing about PTSD treatments quite a bit in The Frontier Psychiatrists newsletter. One is offered at Fermata, the clinic I co-run in Brooklyn. I recently wrote an article about it. We provide Prism treatment for PTSD at our clinic, much like our colleagues at Homebase in Boston, with Veteran Populations.

Sometimes, you’d rather listen. On that note, here is the podcast version of that article.

Other PTSD-themed writing includes…

Medical Cannabis for PTSD?

Prazosin

The ICU is Traumatic For Everyone

As well as a whole… Saga… on MDMA:

Can MDMA-AT Be Saved, Part I

Can MDMA-AT Be Saved, Part II

Should MDMA-AT Be Saved, Part III

Saving MDMA from AT: Part IV

Bad Touch!: MDMA Part V

Saving MDMA (and other psychedelic therapies), Part VI

Saving MDMA VII: This Isn't The First Drug to Have Problems Getting Approved

It’s worth noting I’ll be appearing on a webinar with the Psychedelic Medicine Association to discuss the following…and I’ll include the info from my friend and co-author Dr. Morski, MD, JD:

The FDA Said No, What’s Next? Exploring the Field’s Next Chapter After the MDMA Decision

Register now!

In case you missed the news last week, the FDA officially denied Lykos Therapeutics’ New Drug Application for MDMA-assisted therapy, requesting a new Phase III trial be conducted. 

This was a huge blow to the practitioners and patients who were hoping that MDMA would soon be a legal option to address PTSD, a condition where no other therapy has shown the same levels of efficacy as MDMA-assisted therapy.

So you may have questions, like, “When is the next psychedelic medicine likely to be up for FDA approval” and “Which medicine may be the next to reach that stage?” And you may also want an update on what psychedelics (like ketamine) are legally available and how might they serve as a stand-in for the others while we await FDA approvals.

This month we are truly fortunate to have panelists working in various arenas within psychedelic medicine and research to help lead a discussion regarding what psychedelic options are currently available and what’s to come, including:

* Which psychedelic medicines are next in the FDA pipeline

* When might we see another psychedelic therapy up for FDA approval

* How can we utilize the available psychedelic options in the meantime

...and much more!

Register now!Panelists joining us for this month's event are:

* Owen Muir, MD, DFAACAP | Co-Founder, Fermata; Chief Medical Officer, iRxReminder

* Carlene MacMillan, MD, FCTMSS, DFAACAP | Co-Founder, Fermata; Chief Medical Officer, Osmind

You can learn more about them on our event page.So please join us for this live panel discussion on Thursday, August 29th at 5 pm Pacific, 8 pm Eastern. A link to the recording will be provided afterward if you cannot make it to the live event.Hope to see you all on the 29th!You can find the Psychedelic Medicine Association on Twitter , LinkedIn, and Facebook.In service,Lynn Marie Morski, MD, JDPresident, Psychedelic Medicine Association

This is a public episode. If you'd like to discuss this with other subscribers or get access to bonus episodes, visit thefrontierpsychiatrists.substack.com/subscribe